ライフサイエンスコーパス: moderate to severe

1 in 193 hospitalized individuals ranging from moderate to severe.

2 CoNV thickness increased from moderate to severe (218.2 +/- 46.6 mum to 340.2 +/- 8.7

3 patients with symptomatic heart failure with moderate to severe (3+) or severe (4+) secondary MR were

4 to-severe nonsegmental/generalized vitiligo, moderate-to-severe AA (n = 32), psoriasis (n = 24), or A

5 gel (BPX-05) was recently developed to treat moderate to severe acne vulgaris by directly delivering

6 ty (236.6 mcg/g x 654.9 mcg/g, p = 0.014) or moderate to severe activity (236.6 mcg/g x 1128 mcg/g, p

7 activity into remission, mild activity, and moderate to severe activity groups.

8 atients in remission from those with mild or moderate to severe activity.

9 adults who receive kidneys from donors with moderate to severe acute kidney injury (AKI) have simila

10 ough proven efficacious in the management of moderate to severe acute pain and cancer pain, use of ox

11 n costing less than $51,328 per patient with moderate to severe acute respiratory distress syndrome w

12 Patients with moderate to severe acute respiratory distress syndrome.

13 VT-1161 versus fluconazole in subjects with moderate-to-severe acute VVC.

14 kin transcriptome data from 57 patients with moderate to severe AD and 31 healthy controls.

15 placebo-controlled study of 54 patients with moderate to severe AD randomized (1:1) and treated with

16 ; lesional and nonlesional) with early-onset moderate-to-severe AD (<=6 months) and 17 healthy contro

17 esional tissues and blood from patients with moderate-to-severe AD (n = 246) and age-matched control

18 lesional and nonlesional skin of adults with moderate-to-severe AD and psoriasis.

19 molecular biomarker profile of patients with moderate-to-severe AD and to correlate changes in biomar

20 e and effective oral systemic treatments for moderate-to-severe AD are not yet available.

21 Biopsy specimens from 59 patients with moderate-to-severe AD before and 30 patients 12 weeks af

22 l and nonlesional skin from 59 patients with moderate-to-severe AD treated with anti-IL-22 (fezakinum

23 files of infants/toddlers with recent-onset, moderate-to-severe AD using tape strips.

24 with topical corticosteroids in adults with moderate-to-severe AD, severe pruritus, and inadequate c

25 ppraised evidence on systemic treatments for moderate-to-severe AD.

26 cy and safety of tralokinumab in adults with moderate-to-severe AD.

27 be an effective novel therapeutic agent for moderate-to-severe AD.

28 0 mg) once-daily oral therapy in adults with moderate-to-severe AD.

29 IL-22 blockade in tissues from patients with moderate-to-severe AD.

30 The whole blood transcriptomes of moderate-to-severe adult asthma patients (N = 45:34 resp

31 pting the practice of accepting kidneys with moderate to severe AKI in pediatric kidney transplant re

32 before beer and you'll feel queer" regarding moderate-to-severe alcohol intoxication, whereas subject

33 Moderate-to-severe allergic rhinitis (AR) may increase t

34 d three out of 391 patients (51.9%) reported moderate to severe anxiety (State-Trait Anxiety Inventor

35 Moderate to severe anxiety at ICU admission is associate

36 Moderate to severe aortic regurgitation was reduced from

37 id annulus plane systolic excursion, but not moderate to severe AR or severe prosthesis-patient misma

38 Consecutive patients with >= moderate to severe AR were retrospectively identified fr

39 en) were included; 92.6% of the patients had moderate-to-severe AR, and 30.1% had concomitant mild as

40 d trial with 634 subjects (12-65 years) with moderate-to-severe ARC despite use of symptom-relieving

41 ilated patients aged 16 years and older with moderate to severe ARDS (Pao2:Fio2 <=200 mm Hg) were enr

42 We recruited ventilated patients with moderate to severe ARDS (ratio of partial pressure of ox

43 December 2017) that included 301 adults with moderate to severe ARDS according to the Berlin definiti

44 Patients with COVID-19 and moderate to severe ARDS, according to the Berlin definit

45 Among patients with moderate to severe ARDS, PES-guided PEEP, compared with

46 r randomized controlled trial in adults with moderate to severe ARDS.

47 fter administration of MSCs to patients with moderate to severe ARDS.

48 f intravenous MSCs was safe in patients with moderate to severe ARDS.

49 We randomly assigned patients with moderate-to-severe ARDS (defined by a ratio of the parti

50 olled 1006 patients early after the onset of moderate-to-severe ARDS (median, 7.6 hours after onset).

51 cardiac damage in patients with asymptomatic moderate to severe AS.

52 ol and Prevention advises that patients with moderate to severe asthma belong to a high-risk group th

53 ise healthy children aged 2 to 17 years with moderate to severe asthma defined by a Pediatric Respira

54 o assess the safety of LAIV in children with moderate to severe asthma, and in preschool children wit

55 hed external comparator cohort of women with moderate-to-severe asthma (n = 1153), termed the Quebec

56 Few genetic studies that focus on moderate-to-severe asthma exist.

57 Cases were defined as having moderate-to-severe asthma if they were taking appropriat

58 from bronchial biopsies of 81 patients with moderate-to-severe asthma of the U-BIOPRED cohort.

59 d-on treatment in patients with uncontrolled moderate-to-severe asthma significantly reduced asthma e

60 alizumab) has been used for the treatment of moderate-to-severe asthma that is not controlled by inha

61 iants associated with the risk of developing moderate-to-severe asthma that regulate mucin production

62 total of 33 patients with poorly controlled, moderate-to-severe asthma were scanned with hyperpolariz

63 undertook a genome-wide association study of moderate-to-severe asthma, and in stage 2 we followed up

64 riants for all types of asthma contribute to moderate-to-severe asthma, and provide novel mechanistic

65 wide significant signals of association with moderate-to-severe asthma, including several signals in

66 ntity novel genetic variants associated with moderate-to-severe asthma, see whether previously identi

67 The majority of moderate to severe asthmatics present with a "type 2-hig

68 with likely egg and/or milk allergy, and/or moderate to severe atopic dermatitis (AD) and a positive

69 recently been approved for the treatment of moderate to severe atopic dermatitis (AD) in adults.

70 lpha that improves the signs and symptoms of moderate to severe atopic dermatitis (AD).

71 safety, and pharmacodynamics in adults with moderate to severe atopic dermatitis.

72 se 1 inhibitor upadacitinib in patients with moderate to severe atopic dermatitis.

73 Moderate-to-severe atopic dermatitis (AD) has been assoc

74 ompared to standard of care for uncontrolled moderate-to-severe atopic dermatitis (AD).

75 ADE MONO-1), patients (aged >=12 years) with moderate-to-severe atopic dermatitis (Investigator Globa

76 ibody used in the treatment of patients with moderate-to-severe atopic dermatitis (msAD).

77 effective and well tolerated in adults with moderate-to-severe atopic dermatitis in a phase 2b trial

78 ell tolerated in adolescents and adults with moderate-to-severe atopic dermatitis.

79 b monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis.

80 head positioning and strabismus in cases of moderate to severe baseline head positioning.

81 from June 2008 to June 2018 in patients with moderate to severe benign prostatic hyperplasia-related

82 ial was conducted in 406 adult patients with moderate-to-severe birch pollen-induced allergic rhinoco

83 women; 72% underwent complex operations; 95% moderate to severe bleeding; and pretreatment fibrinogen

84 eter interventions in the coronary arteries, moderate-to-severe calcification portends lower procedur

85 erences in FIBTEM variables between mild and moderate to severe cases (median amplitude at 10 min, 13

86 iffered significantly between mild cases and moderate to severe cases: median clotting time 56 s (ran

87 In adults with moderate to severe CATD receiving cholinesterase inhibit

88 a double-blind, phase 2 trial in adults with moderate to severe CD and inadequate response or intoler

89 t in patients without prior heart failure or moderate to severe chronic kidney disease.

90 ints in patients with prior heart failure or moderate to severe chronic kidney disease.

91 disease in patients with type 2 diabetes and moderate-to-severe chronic kidney disease.

92 onfounders, we studied 2738 individuals with moderate to severe CKD participating in the multicenter

93 In a cohort of individuals with moderate to severe CKD, we observed steep declines of eG

94 Patients (n = 323) 18 years and older with moderate-to-severe congestion and NPs were randomized to

95 0.3 mm(3), P = .025, respectively) and from moderate to severe CoNV (44.6 +/- 5.3%, P < .001, and 2.

96 higher OPN concentrations in tissue showing moderate to severe COPD compared to that in controls.

97 The rate of moderate to severe COPD exacerbations was reduced over t

98 e GRS (P > 0.10), improved discrimination of moderate-to-severe COPD cases relative to clinical facto

99 ects with severe asthma and 78 subjects with moderate-to-severe COPD in a prospective single centre t

100 In terms of secondary tissue injury, moderate-to-severe cortical superficial siderosis was as

101 Moderate-to-severe cortical superficial siderosis was as

102 Adult patients with confirmed moderate to severe COVID were included.

103 The clinical manifestation of moderate to severe COVID-19 has parallels to secondary h

104 ourse of methylprednisolone in patients with moderate to severe COVID-19 reduced escalation of care a

105 ission exists through tears in patients with moderate to severe COVID-19.

106 rs of 24% of patients with laboratory-proven moderate to severe COVID-19.

107 arly corticosteroid therapy in patients with moderate to severe COVID-19.

108 ventilated patients (aged 40-75 years) with moderate-to-severe COVID-19 ARDS were included.

109 Patients with moderate-to-severe COVID-19 pneumonia are likely to bene

110 ess to 10-21 day of illness in patients with moderate-to-severe COVID-19, but not in those with mild

111 ough ustekinumab is an effective therapy for moderate to severe Crohn's disease (CD), its effects on

112 Moderate-to-severe CRS is managed with the IL-6 receptor

113 f treatment, the proportion of patients with moderate-to-severe CRSwNP (VAS > 3-10) decreased from 86

114 ety, and tolerability at 2 concentrations in moderate-to-severe DED.

115 d substantial recovery (mRS <2) and 17 (15%) moderate to severe deficits (mRS >2; one died).

116 Patients with moderate-to-severe degenerative cervical myelopathy aged

117 eyond decompressive surgery in patients with moderate-to-severe degenerative cervical myelopathy.

118 ine (used alone or as an add-on therapy) for moderate to severe dementia.

119 are limited to MDD patients ranging between moderate to severe depression and the effects of medicat

120 =0.200) and prospectively predicted onset of moderate to severe depressive symptoms (hazard ratio=1.2

121 scherichia coli (EPEC) is a leading cause of moderate to severe diarrhea among young children in deve

122 Moderate to severe diarrhea caused by Shigella is a glob

123 gen Shigella is one of the leading causes of moderate-to-severe diarrhea and death in young children

124 etiology, and sequelae of medically attended moderate-to-severe diarrhoea (MSD) among children aged 0

125 d the burden, aetiology, and consequences of moderate-to-severe diarrhoea (MSD) in children aged 0-59

126 Children with moderate-to-severe diarrhoea and age-matched and communi

127 co-infection adjusted odds ratios (aORs) for moderate-to-severe diarrhoea associated with typical ent

128 shigella-related mortality and the effect of moderate-to-severe diarrhoea episodes to determine the n

129 though Shigella spp remained associated with moderate-to-severe diarrhoea in both nutritional groups.

130 ween acute malnutrition and mortality during moderate-to-severe diarrhoea in children is not limited

131 months also had a stronger association with moderate-to-severe diarrhoea in children with acute maln

132 shigella are two major pathogens that cause moderate-to-severe diarrhoea in children younger than 5

133 d associations between enteric pathogens and moderate-to-severe diarrhoea in conditional logistic reg

134 ggested they had a stronger association with moderate-to-severe diarrhoea than other pathogens among

135 92 (64%) of 144 children with moderate-to-severe diarrhoea who died had acute malnutri

136 ciation between common enteric pathogens and moderate-to-severe diarrhoea, and whether associations b

137 Among children with moderate-to-severe diarrhoea, Cox proportional hazards r

138 associations between specific pathogens and moderate-to-severe diarrhoea.

139 Forty-five percent of the cohort had moderate to severe disability (modified Rankin score, 3-

140 e colitis (UC) present with, or progress to, moderate to severe disease activity.

141 25117; ongoing, not recruiting), adults with moderate to severe disease and inadequate control by top

142 ive years with IBS-C (Rome III criteria) and moderate to severe disease at inclusion (IBS Symptom Sev

143 titis, with 6.6 million meeting criteria for moderate to severe disease.

144 ge 31 years (healthy, mild periodontitis, or moderate-to-severe disease).

145 (AD) are largely restricted to patients with moderate-to-severe disease.

146 inhibitors are highly effective therapy for moderate-to-severe disease.

147 In influenza patients with moderate-to-severe diseases, we uncover a complex landsc

148 multicenter clinical trial for patients with moderate-to-severe DR treated with AKB-9778 and followed

149 and minimally invasive outcome measures for moderate to severe dry eye disease.

150 with CPP, regardless of diagnosis, reported moderate to severe dysmenorrhea and non-cyclical pelvic

151 6.60; P = 0.03); however, nurse detection of moderate to severe dyspnea was not significantly associa

152 Across all three raters, the frequency of moderate to severe dyspnea was similar or greater than t

153 s had good agreement with patient reports of moderate to severe dyspnea.

154 Annual moderate to severe exacerbation rates (aclidinium, 0.44;

155 icipants aged 18 years or older with PBC and moderate to severe fatigue were randomized to receive tw

156 accuracy for identifying case children with moderate to severe fibrosis (area under the receiver ope

157 ed in the fecal microbiomes of patients with moderate to severe fibrosis (P < .001).

158 edictor of the need for TPK in patients with moderate-to-severe filamentous fungal keratitis.

159 ve reconstruction system in the treatment of moderate to severe functional TR in 30 patients enrolled

160 to be safe in patients with symptomatic and moderate to severe functional TR.

161 to patients who are undergoing treatment for moderate to severe glaucoma, many of which may serve as

162 in future evaluations of new treatments for moderate to severe glaucoma.

163 Stroke patients presented with moderate to severe hand motor deficits.

164 t in adolescents (aged >=12) and adults with moderate to severe HDM-induced allergic rhinitis.

165 Ninety-six percent of patients had moderate to severe head positioning at baseline.

166 a large number of genes are responsible for moderate to severe hearing loss in sporadic individuals

167 Twenty-one individuals with moderate to severe hearing loss were recruited.

168 RRB was implicated for recessively inherited moderate to severe hearing loss.

169 We compared the prevalence of moderate-to-severe hepatic steatosis (M-HS) in PWH with

170 Moderate-to-severe hepatic steatosis is less common in P

171 Moderate-to-severe hepatic steatosis was assessed by une

172 nd Drug Administration for the management of moderate to severe hidradenitis suppurativa.

173 nd Drug Administration for the management of moderate to severe hidradenitis suppurativa.

174 neurodevelopmental outcome of neonates with moderate to severe HIE.

175 therapy to date shown to improve outcome in moderate to severe HIE; however, assessment of severity

176 dose cohorts of bermekimab in patients with moderate-to-severe HS who are naive to or have failed pr

177 resent a new therapeutic option for treating moderate-to-severe HS.

178 Twenty-four of 44 (55%) patients developed moderate to severe hypophosphataemia (serum phosphate <

179 .90 to 1.63), and admission to the NICU with moderate-to-severe hypoxic-ischemic encephalopathy at da

180 the neonatal intensive care unit (NICU) with moderate-to-severe hypoxic-ischemic encephalopathy at da

181 ion with respect to early neonatal death and moderate-to-severe hypoxic-ischemic encephalopathy.

182 Direct and indirect costs for moderate to severe IBS-C were high with the largest dire

183 Both of these variants were segregating with moderate to severe ID, microcephaly, and various facial

184 he end of follow-up, abnormal VA (considered moderate to severe impairment) in the more severely affe

185 ient-reported outcomes, 6 to 12 months after moderate to severe injury.

186 We contacted adult patients with a moderate-to-severe injury from a firearm or motor vehicl

187 ic de novo missense variants in PAK1 lead to moderate-to-severe intellectual disability, macrocephaly

188 Among 70 grafts with moderate to severe IRI, 42.9% of grafts developed EAD, a

189 e identified as independent risk factors for moderate to severe IRI.

190 l microhemorrhage is common in patients with moderate to severe ITP.

191 younger than 18 years, those with trauma or moderate to severe liver disease, and those who had rece

192 in patients with decompensated cirrhosis and moderate-to-severe liver failure from nine university ho

193 nts born before post-conception week 25 have moderate-to-severe long-term neurodevelopmental impairme

194 validated the array by testing patients with moderate to severe ME/CFS patients and healthy controls.

195 Thirteen infants (69% male) >=36 weeks with moderate-to-severe NE were enrolled.

196 Moderate to severe neurological impairment was present i

197 ediatric stroke are generally favorable, but moderate to severe neurological impairments are still co

198 percent (95% CI, 21%-31%) of children showed moderate to severe neurological sequelae at discharge.

199 The study enrolled adults with moderate to severe nonpsychotic depression and a history

200 (+) T cells in the blood of 19 patients with moderate-to-severe nonsegmental/generalized vitiligo, mo

201 Similarly, patients with moderate to severe NPDR had a higher risk of each outcom

202 ) eyes, PDR without DME in 3 (23%) eyes, and moderate to severe NPDR with DME in 3 (23%) eyes.

203 Among patients with moderate to severe OA of the knee or hip and inadequate

204 tment of daytime sleepiness in patients with moderate to severe obstructive sleep apnea refusing cont

205 llion (399-450) adults aged 30-69 years have moderate to severe obstructive sleep apnoea globally.

206 and March 2018, and focused on patients with moderate-to-severe ocular irAEs following anti-PD-(L)1.

207 An additional 5 cases of moderate-to-severe ocular irAEs were reported through th

208 e main outcome measure was the prevalence of moderate-to-severe ocular irAEs.

209 ured interviews with patients diagnosed with moderate to severe open-angle glaucoma, focusing on outc

210 urgitation) trial, 614 patients with HF with moderate-to-severe or severe SMR were randomized to TMVr

211 pressure (CPAP) withdrawal in patients with moderate to severe OSA.

212 54.9 mum, P = .048, respectively), not from moderate to severe (P = .999 and P = .403, respectively)

213 Few participants complained of moderate to severe pain in any group immediately after t

214 Nurse detection of moderate to severe pain was significantly associated wit

215 r were estimated for groups with and without moderate to severe pain, and these risk differences were

216 onists have been widely applied for treating moderate to severe pain.

217 aphic follow-up demonstrated similar rate of moderate-to-severe paravalvular aortic regurgitation (Ev

218 ever, after propensity matching, the rate of moderate-to-severe paravalvular leak became significantl

219 her rates of aortic root injury (p < 0.001), moderate-to-severe paravalvular regurgitation (p = 0.002

220 art information, physicians classified their moderate-to-severe patients into one of the following ca

221 IFN and inflammatory cytokine patterns in 32 moderate-to-severe patients with COVID-19 hospitalized f

222 221 patients, including 608 with generalized moderate to severe periodontitis (periodontitis group) a

223 d without EMD in 51 patients presenting with moderate to severe periodontitis (PPD = 5 to 8 mm) in at

224 e lowest early-life SEP had a higher risk of moderate-to-severe periodontitis controlled for mediator

225 s application is limited to the treatment of moderate-to-severe persistent asthma and chronic spontan

226 with uncontrolled, persistent (phase 2b), or moderate-to-severe (phase 3) asthma.

227 ics as an option for first-line treatment of moderate to severe plaque psoriasis because of their eff

228 mab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis in Subjects]) partic

229 Therapeutic advancements for moderate to severe plaque psoriasis include biologics th

230 ithdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects], -2 [P3 St

231 ntrolled, exploratory trial in patients with moderate to severe plaque psoriasis without clinical CV

232 ts], -2 [P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis], and -3 [Efficacy a

233 n oral TYK2/Jak1 inhibitor, in patients with moderate-to-severe plaque psoriasis (NCT02969018).

234 oved and are used as first line treatment of moderate-to-severe plaque psoriasis and psoriatic arthri

235 al skin biopsy samples from 81 patients with moderate-to-severe plaque psoriasis participating in 2 d

236 in providing skin clearance in patients with moderate-to-severe plaque psoriasis.

237 isankizumab with adalimumab in patients with moderate-to-severe plaque psoriasis.

238 ffective and well tolerated in patients with moderate-to-severe plaque psoriasis.

239 le patients were aged 18 years or older, had moderate-to-severe plaque-type psoriasis, and were candi

240 otentially life-threatening in patients with moderate to severe primary immunodeficiency disorders.

241 ferred even longer in female recipients with moderate to severe proteinuria, uncontrolled hypertensio

242 , as compared with placebo, in patients with moderate-to-severe prurigo nodularis and severe pruritus

243 Moderate-to-severe prurigo nodularis was defined as 20 o

244 Patients with moderate to severe pruritus (>=5 of 10 on visual analog

245 afibrate is superior to placebo in improving moderate to severe pruritus in patients with PSC and PBC

246 Moderate to severe pruritus was more common in patients

247 ned patients undergoing hemodialysis who had moderate-to-severe pruritus to receive either intravenou

248 ants included 68 white and black adults with moderate to severe psoriasis who had and had not receive

249 This cohort included moderate-to-severe psoriasis patients treated with 140 m

250 double-blind treatment period, patients with moderate-to-severe psoriasis received secukinumab for 40

251 Patients (n = 30) with moderate-to-severe psoriasis were randomized to once-dai

252 s international case series of patients with moderate-to-severe psoriasis, biologic use was associate

253 ose metabolism in the blood of patients with moderate-to-severe psoriasis.

254 rleukin (IL)-23 and IL-17A effectively treat moderate-to-severe psoriasis.

255 ocess when selecting a biologic for treating moderate-to-severe psoriasis.

256 ologics have revolutionized the treatment of moderate-to-severe psoriasis.

257 non-verbal); intellectual disability in the moderate to severe range; mild hypotonia in infancy foll

258 Any and moderate to severe relapse occurred in 62% of participan

259 et allergic asthma, (2) early-onset allergic moderate-to-severe remodeled asthma, (3) late-onset nona

260 the respiratory system of humans, leading to moderate-to-severe respiratory diseases.

261 city (FVC) < 80% predicted] vs. 21.2% with a moderate-to-severe restrictive spirometric pattern [FVC

262 In multivariable-adjusted analyses, a moderate-to-severe restrictive spirometric pattern was a

263 ical cohort of adult patients suffering from moderate-to-severe rhino-conjunctivitis with or without

264 effective, and recommended in patients with moderate to severe SSR and in patients with SSR confined

265 CKD, even in moderate to severe stages, is associated with an increas

266 s are decreased in very preterm infants with moderate-to-severe structural cerebellar injury.

267 resulting in 3.5 million (0.8-5.4) cases of moderate-to-severe stunting and 44 400 (29 400-59 800) t

268 well in predicting COVID-19 in patients with moderate to severe symptoms and has substantial interobs

269 een primarily restricted to individuals with moderate to severe symptoms due to limited test availabi

270 system is meant to be used in patients with moderate to severe symptoms of COVID-19.

271 avirus-negative diarrhea, and higher risk of moderate-to-severe symptoms when experiencing RVGE.

272 ults from different parts of the world, with moderate-to-severe symptoms, impairment of quality of li

273 patients is highly variable and can include moderate to severe systemic inflammation and/or marked s

274 Among patients with moderate to severe TBI, out-of-hospital tranexamic acid

275 Class II patients were more likely to have moderate-to-severe TBI, to be admitted on weekends, to u

276 From a sample of 96 patients surviving moderate-to-severe TBI, we performed shape analysis of l

277 81.5 vs 81.7%, 77.5-85.3; p=0.1586) and late moderate to severe toxicity (16.5%, 95% CI 12.9-20.7 vs

278 Proportions of acute moderate to severe toxicity (77.4%, 95% CI 73.0-81.5 vs

279 rns, including electrographic seizures after moderate-to-severe traumatic brain injury and to correla

280 in this prospective cohort of patients with moderate-to-severe traumatic brain injury.

281 Decisions about optimal drug therapy in moderate to severe UC are complex, with limited guidance

282 Focused questions in adult outpatients with moderate to severe UC included: (1) overall and comparat

283 management of outpatients or inpatients with moderate to severe UC often requires the use of immunomo

284 ism, presenteeism and productivity losses in moderate to severe UC.

285 immunomodulator and/or biologic therapy for moderate to severe UC.

286 scribing the indirect costs in patients with moderate to severe UC.

287 Among patients with moderate-to-severe UC in the US and EU5, active disease

288 ontrolled trial of ozanimod in patients with moderate-to-severe ulcerative colitis (n=179).

289 )beta(7) antibody abrilumab in patients with moderate-to-severe ulcerative colitis despite treatment

290 sponse, and mucosal healing in patients with moderate-to-severe ulcerative colitis.

291 g and maintaining remission in patients with moderate-to-severe ulcerative colitis.

292 umab improves lung function in patients with moderate-to-severe uncontrolled asthma, but its effects

293 al centers between March and April 2020 with moderate to severe upper respiratory symptoms suspicious

294 All participants had moderate to severe upper-limb weakness and were randomis

295 normal appearing nerves at presentation, had moderate to severe VA loss at long term follow-up.

296 n of combined age-standardized prevalence of moderate-to-severe vision impairment (MSVI) across all w

297 AFLD had a significant association only with moderate to severe WMH (OR: 1.64, 95% CI: 1.10-2.42), ev

298 verity of NAFLD fibrosis and the presence of moderate to severe WMH (p for trend <0.001).

299 significant association with the presence of moderate to severe WMH in cognitively normal individuals

300 , and NAFLD severity predicted more frequent moderate to severe WMH.